Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary ...

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis The IGNITE study, which evaluated two dose strengths of ...

32.8% of rocatinlimab-treated patients achieved the co-primary endpoint of EASI 75 by week 24. 19.3% reached the other co-primary endpoint, defined as a validated IGA-AD score of 0 or 1 by week 24.

The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose ...

Also Read: Amgen And Kyowa Kirin’s Rocatinlimab Reduces Eczema Severity In Phase 3 Study Change from baseline in the Quantitative Myasthenia Gravis (QMG) score was also greater for patients in ...

Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing therapy rocatinlimab in atopic dermatitis (AD). The 24-week IGNITE study, which ...

The phase 3 ROCKET-Horizon trial testing rocatinlimab, a first-in-class investigational T-cell rebalancing therapy, meets its co-primary end points in week 24: EASI75 response was 32.8% for ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.